INmune Bio (INMB) Stock Highlights

4.4 | -0.45%

2024-12-21 06:39:24

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patients innate immune system to allow the immune system to fight cancer. The companys pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Statistics

Range Today

4.32 4.6

Volume Today 402.2K

Range 1 Year

4.36 14.74

Volume 1 Year 41.86M

Range 3 Year

4.36 14.74

Volume 3 Year 81.33M

Range 10 Year

2.2 30.37

Volume 10 Year 256.94M

Highlights

Market Capitalization 135.92M (small)

Floating Shares 14.31M

Current Price 4.4

Price To Earnings -2.88

Price To Revenue 2.51K

Price To Book 3.51

Earnings Per Share -2.15

Payout Ratio 0%

Performance

Latest -0.45%

1 Month -6.38%

3 Months -17.91%

6 Months -42.93%

1 Year -57.07%

3 Years -57.69%

5 Years -28.1%

10 Years -47.87%

Benchmarks

Market Capitalization

219 / 368

Gross Profits

136 / 278

Total Revenue

269 / 300

Total Rank

158 / 368

Free Cashflow

65 / 352

Performance 5 years

144 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.